As previously reported, Cantor Fitzgerald assumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and a price target of ...

Vertex Pharmaceuticals Inc. closed 5.66% below its 52-week high of $519.88, which the company reached on November 8th.

Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $462 from $459 and keeps an Equal Weight rating on the ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective increased by Bank of America from $555.00 to $567.00 in a research note issued on Monday,Benzinga reports.

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Analysts' ratings for Vertex Pharmaceuticals VRTX over the last quarter vary from bullish to bearish, as provided by 17 analysts. The table below summarizes their recent ratings, showcasing the ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...